New hope for aggressive brain cancer: radiation plus immunotherapy shows promise
NCT ID NCT02866747
First seen Apr 20, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study tested whether adding an immunotherapy drug (durvalumab) to targeted radiation therapy can help people with recurrent glioblastoma, an aggressive brain cancer. About 108 adults whose cancer returned after previous treatments took part. The goal was to see if the combination improves survival and controls tumor growth better than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Francois Baclesse
Caen, 14 000, France
-
Centre Georges Francois Leclerc
Dijon, 21 000, France
-
Centre Paul Strauss
Strasbourg, 67000, France
-
Hopital Avicenne
Bobigny, 93 000, France
-
Hopital Pitie Salpetriere
Paris, 75013, France
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Saint-Cloud, 92 210, France
-
Institut Gustave Roussy
Villejuif, 94 800, France
-
Institut Regional Du Cancer de Montpellier
Montpellier, 34 298, France
-
Institut de Cancerologie de L'Ouest
Angers, 49055, France
Conditions
Explore the condition pages connected to this study.